CAR-T cell therapies for blood cancers and solid tumors are being developed by our own significant internal R&D team, based on our comprehensive experience in gene editing, cell therapy and immunotherapy.
Advanced, Clinical Stage CAR-T Platform
IND cleared by U.S. FDA for ICTCAR014 — IRB-approved human trials in China demonstrated 92.3% ORR (53.8% CR; 38.5% PR), significant tumor shrinkage and limited toxicity. IND cleared by China FDA for ICTCAR003.
for Solid Tumors
IRB-approved human trials being conducted in China with in-house developed CoupledCARTM technology in a range of solid tumor indications.
Better CAR-T Therapy for
Both Liquid and Solid Tumors
Discover our broad pipeline of next generation CAR-T immunotherapies.